The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients

Shuquan Gao1 | Jun Xue1 | Xueliang Wu1 | Tingting Zhong2 | Yingchun Zhang1 | Shaoding Li1

1Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China
2Department of Neurology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China

Correspondence
Jun Xue, Department of General Surgery, The First Affiliated Hospital of Hebei North University, No.12 Changqing Road, Zhangjiakou 075000, China.
Email: 443784736@qq.com

Funding information
Scientific Research fund of Hebei Health Commission, Grant/Award Number: 20180813

Abstract

Background: Cell division control protein 42 (CDC42) is involved in colorectal cancer (CRC) progression by modulating CD8+ T cell activation, immune escape, and direct oncogenetic biological processes. This study aimed to explore the correlation of blood CDC42 with disease risk, comorbidities, disease features, tumor markers, and prognosis among CRC patients.

Methods: CDC42 in peripheral blood mononuclear cells was detected by reverse transcription-quantitative polymerase chain reaction from 250 resectable CRC patients and 50 healthy controls (HCs). CDC42 was divided by quartiles, as well as high and low expressions in CRC patients for correlation and survival analysis.

Results: CDC42 was elevated in CRC patients vs. HCs (p < 0.001), which had a good ability to distinguish CRC patients from HCs with the area under the curve (95% confidence interval) of 0.889 (0.841–0.937). In CRC patients, CDC42 was not associated with demographics or comorbidities (all p > 0.05), while its higher quartile was linked to increased T stage (p < 0.001), N stage (p = 0.009), TNM stage (p < 0.001), abnormal carcinoembryonic antigen (p = 0.043), and adjuvant chemotherapy administration (p = 0.002). Higher CDC42 quartile (p = 0.002) and CDC42 high (vs. low) (p < 0.001) were related to worse disease-free survival (DFS); meanwhile, elevated CDC42 quartile (p = 0.002) and CDC42 high (vs. low) (p = 0.001) were also linked to poor overall survival (OS). Multivariate Cox’s regression analysis presented that CDC42 quartile 3 and 4 (vs. quartile 1) independently predicted declined DFS and OS (all p < 0.05).

Conclusion: Circulating CDC42 relates to higher disease risk, T, N, and TNM stage, abnormal tumor marker, and poor prognosis among CRC patients.

KEYWORDS
blood CDC42, colorectal cancer, DFS, disease characteristics, OS
1 | INTRODUCTION

Colorectal cancer (CRC) is one of the most prevalent malignancies and the second leading cause of cancerous deaths in 2020, with hyperlipidemia, obesity, and alcohol consumption as its main risk factors.1-3 Currently, many CRC patients are diagnosed at an early stage due to the development of screening by colonoscopy, while some heterogeneous tumors may be ignored by this procedure; besides, coloscopy is invasive and uncomfortable, which may induce harm to patients.4,5 Meanwhile, a proportion of CRC patients do not receive optimal treatment partly due to lacking reliable predictive factors for prognosis, which leads to dismal clinical outcomes among patients.6,7 Thus, the exploration of convenient, accessible, and reliable biomarkers is imperative to improving the management of CRC patients.

Cell division control protein 42 (CDC42), a small GTPase belonging to the Rho family, plays an important role in regulating several crucial tumor biological processes through modulating actin cytoskeleton remodeling, cell adhesion, vesicle transport, transcriptional activation, gene expression, and cell cycle regulation.8,9 For instance, CDC42 is involved in tumor acceleration via suppressing CD8+ T cells10,11; meanwhile, CDC42 has the capacity of promoting the immune escape of tumor cells12,13; moreover, CDC42 is also able to directly regulate malignant functions of CRC cells, including promoting proliferation, migration, and invasion.14-16 Therefore, the above-mentioned data present that CDC42 might take part in tumorigenesis and progression of CRC. Interestingly, it has been reported that CDC42 is related to a higher risk of breast cancer17; it also is linked to unfavorable survival among lung cancer patients.18 Taken together, we deduced that blood CDC42 might serve as a convenient and available biomarker for CRC diagnosis and prognosis, while related data is scarce.

Therefore, the present study aimed to explore the association of blood CDC42 with disease risk, comorbidities, tumor features/markers, and prognosis among CRC patients.

2 | METHODS

2.1 | Participants

A total of 250 resectable first-ever CRC patients who underwent surgical resection between January 2017 and December 2020 were consecutively enrolled. The inclusion criteria for CRC patients: (1) histologically confirmed primary CRC; (2) resectable CRC; and (3) aged ≥18 years. The exclusion criteria for CRC patients: (1) had distant metastases; (2) had other malignancies; (3) accompanied with autoimmune diseases or hematological malignancies; (4) history of CRC; and (5) pregnant or nursing women. Besides, 50 age- and sex-matched people were also enrolled as healthy controls (HCs). The inclusion criteria for HCs were (1) aged ≥18 years and (2) proved good health by physical examination in our hospital. The exclusion criteria for HCs were the same as for CRC patients. The study was approved by the Ethical Committee of our hospital. The written informed consent was provided by each subject.

2.2 | Clinical data

After enrollment, we collected the demographics, comorbidities, tumor features, tumor marker, and adjuvant treatment information of patients using case report form. The demographics included the followings: age; gender (female or male); and smoker (yes/no). The comorbidities included the followings: hypertension (yes/no); hyperlipidemia (yes/no); and diabetes (yes/no). The tumor features included the followings: diagnosis (colon or rectum); Eastern Cooperative Oncology Group Performance Status (ECOG PS); tumor differentiation (well or moderate or poor); tumor size; T/N/M/TNM stage. The tumor marker included carcinoembryonic antigen (CEA), and CEA ≥5 ng/mL was considered CEA abnormal. The treatment information included the followings: adjuvant chemotherapy (yes/no) and adjuvant regimen (Capecitabine or capecitabine plus oxaliplatin). After 2 weeks of adjuvant chemotherapy, the drug was discontinued for 1 week, and 3 weeks were used as a cycle of treatment, for a total of 8 cycles of treatment. Besides, the age and gender of HCs were also recorded.

2.3 | Blood sample collection

The peripheral blood (PB) samples of CRC patients were collected by venipuncture within 24 h after admission. The PB samples of HCs were also collected during physical examination. After collection, peripheral blood mononuclear cells (PBMCs) were isolated from PB samples by Ficoll-Paque density gradient centrifugation (2500 revolutions per minute, 30 min, without brake).

2.4 | RT-qPCR assay

RT-qPCR assay was carried out for quantitative analysis of the expression of CDC42 in the PBMCs. In brief, total RNA was extracted by QIAamp RNA Blood Mini Kit (Qiagen) and reversely transcribed by iScript™ cDNA Synthesis Kit (Bio-Rad). Afterward, qPCR was performed by TB Green™ Fast qPCR Mix (Takara). After incubated at 95°C for 5 min, the qPCR was performed by 30 cycles of 95°C for 30 sec, 55°C for 1 min, and 70°C for 1 min. Among these, GAPDH was used as the internal reference. Specific primers for qPCR were as follows: primers for CDC42, forward: 5′-CCATCGGAATATGTCGTAATCTGTCA-3′; reverse: 5′-CTCAGCGTCTGAATCTGTCA-3′. GAPDH was used as an internal control. Primers for GAPDH, forward: 5′-GAGTCCACTGGCCTTCATC-3′; reverse: 5′-ATCTTGGAGGCCTGTGTCACTTCT-3′. The expression of CDC42 was calculated by the 2^-ΔΔCT method.19
2.5 | Follow-up

After tumor resection, CRC patients were regularly followed up. The follow-up plan was 1–2 months for the first half year, 3–6 months for the next half year and every 6 months from the second year. Disease-free survival (DFS) and overall survival (OS) were estimated by the follow-up records of CRC patients. In survival analyses, thirty-eight CRC patients who lost to follow-up were processed as censored data.

2.6 | Statistics

The 25th, 50th, and 75th percentile of CDC42 in CRC patients were 2.064, 2.641, and 3.906, respectively. In association analysis, CDC42 in CRC patients was classified as quartile 1 (≤25th percentile), quartile 2 (25th–50th percentile), quartile 3 (50th–75th percentile), and quartile 4 (>75th percentile). In survival analysis, CDC42 in CRC patients was divided as low expression (≤50th percentile) and high expression (>50th percentile).

The comparisons of CDC42 between different subjects were assessed using Mann–Whitney U test. The profile of CDC42 in differentiating subjects was estimated using the receiver-operating characteristic (ROC) curve. The associations between CDC42 quartiles and demographics, comorbidities, tumor features or adjuvant treatment information were evaluated using the Mantel–Haenszel Chi-square test or Chi-square test.

The correlation of CDC42 (high or low) with DFS and OS was examined by the Kaplan–Meier method and Log-rank test. The prognostic value was estimated using Cox’s proportional hazard regression model analysis with forward-stepwise mode. A p value <0.05 indicated a statistical significance. The statistical analyses were performed using SPSS V.26.0 (IBM Corp.). The figures were plotted using GraphPad Prism V.7.02 (GraphPad Software Inc.).

3 | RESULTS

3.1 | Baseline characteristics of CRC patients

Among 250 CRC patients, the mean age was 63.0 ± 10.9 years; besides, there were 89 (35.6%) females and 161 (64.4%) males. Furthermore, there were 79 (31.6%), 39 (15.6%), and 33 (13.2%) patients with hypertension, hyperlipidemia, and diabetes, respectively. Moreover, there were 132 (52.8%) and 118 (47.2%) patients with ECOG PS scores of 0 and 1, respectively. Additionally, 46 (18.4%), 117 (46.8%), and 87 (34.8%) patients possessed well, moderate, and poor tumor differentiation, accordingly. Meanwhile, there were 33 (13.2%), 121 (48.4%), and 96 (38.4%) patients with TNM stages of I, II, and III, respectively. In addition, 196 (78.4%) patients received adjuvant chemotherapy, among which 48 (19.2%) patients were administered with capecitabine and 148 (59.2%) received capecitabine plus oxaliplatin (Table 1).

| TABLE 1 Baseline characteristics of CRC patients |
|-----------------------------------------------|
| Items                                         |
| Demographics                                  |
| Age (years), mean ± SD                        |
| Gender, n (%)                                 |
| Female                                        |
| Male                                          |
| Smoker, n (%)                                 |
| Comorbidities                                 |
| Hypertension, n (%)                           |
| Hyperlipidemia, n (%)                         |
| Diabetes, n (%)                               |
| Tumor features                                |
| Diagnosis, n (%)                              |
| Colon                                         |
| Rectum                                        |
| ECOG PS, n (%)                                |
| 0                                             |
| 1                                             |
| Tumor differentiation, n (%)                  |
| Well                                           |
| Moderate                                      |
| Poor                                          |
| Tumor size, n (%)                             |
| <5 cm                                         |
| ≥5 cm                                         |
| T stage, n (%)                                |
| T1                                            |
| T2                                            |
| T3                                            |
| T4                                            |
| N stage, n (%)                                |
| N0                                            |
| N1                                            |
| N2                                            |
| M stage, n (%)                                |
| M0                                            |
| TNM stage, n (%)                              |
| Stage I                                       |
| Stage II                                      |
| Stage III                                     |
| CEA marker                                    |
| Normal (<5 ng/mL)                             |
| Abnormal (≥5 ng/mL)                           |

(Continues)
Comparison of CDC42 between CRC patients and HCs

CDC42 was elevated in CRC patients compared to HCs (median (interquartile range): 2.641 (2.064–3.906) vs. 0.992 (0.790–1.591), \( p < 0.001 \) (Figure 1A). Moreover, CDC42 had a good ability to discriminate CRC patients from HCs with an area under the curve (95% confidence interval) of 0.889 (0.841–0.937); meanwhile, CDC42 was 1.891 at the best cut-off point with sensitivity of 81.2% and specificity of 84.0%, respectively (Figure 1B).

Correlation of CDC42 with demographics, comorbidities, tumor features, tumor marker, and adjuvant treatment information in CRC patients

CDC42 in CRC patients was classified as quartile 1 (≤25th percentile), quartile 2 (25th-50th percentile), quartile 3 (50th-75th percentile), and quartile 4 (>75th percentile) in association analysis, which revealed that no correlation was found in CDC42 quartile with age, gender, smoking, hypertension, hyperlipidemia, or diabetes (all \( p > 0.05 \); Table 2). In addition, elevated CDC42 quartile was linked to increased T stage (\( p < 0.001 \)), N stage (\( p = 0.009 \)), TNM stage (\( p < 0.001 \)), abnormal carcinoembryonic antigen (CEA; \( p = 0.043 \)), and adjuvant chemotherapy (\( p = 0.002 \)), while CDC42 quartile was not correlated with diagnosis as colon cancer or rectum cancer, ECOG PS score, tumor differentiation, tumor size, or adjuvant regimen (all \( p > 0.05 \); Table 3).

Association of CDC42 with DFS and OS in CRC patients

Until the last follow-up, 55 (22.0%) patients had recurrence and 32 (12.8%) patients died. Apart from the classification by quartiles, CDC42 was also divided into low expression (≤50th percentile) and high expression (>50th percentile) to explore the association of CDC42 with prognosis.

A higher CDC42 quartile (\( p = 0.002 \); Figure 2A) and CDC42 high (vs. low; \( p < 0.001 \); Figure 2B) were related to worse DFS. In detail, the 5-year DFS rate among patients with CDC42 quartile 1, 2, 3, and 4 were 82.4%, 77.7%, 62.5%, and 55.3%, respectively; meanwhile, 5-year DFS rate among patients with CDC42 low and high was 79.5% and 59.7%, accordingly.

In addition, a higher CDC42 quartile (\( p = 0.002 \); Figure 3A) and CDC42 high (vs. low; \( p = 0.001 \); Figure 3B) were also linked to poor OS. Detailly, the 5-year OS rate among patients with CDC42 quartile 1, 2, 3, and 4 was 93.8%, 84.4%, 68.2%, and 67.3%, respectively; meanwhile, the 5-year OS rate among patients with CDC42 low and high was 89.4% and 68.1%, accordingly.

Independent factors related to DFS in CRC patients

Multivariate Cox’s proportional hazards regression analysis presented that CDC42 quartile 3 (vs. quartile 1) (hazard ratio [HR] = 2.874, \( p = 0.024 \)), CDC42 quartile 4 (vs. quartile 1) (HR = 3.398, \( p = 0.007 \)), ECOG PS score of 1 (vs. 0) (HR = 1.976, \( p = 0.017 \)), poor (vs. well) tumor differentiation (HR = 3.513, \( p = 0.042 \)), T4 (vs. T1 or T2) stage (HR = 60.463, \( p < 0.001 \)), and N2 (vs. N0) stage (HR = 3.221, \( p < 0.001 \)) were independently correlated with declined DFS (Table 4).
3.6 | Independent factors related to OS in CRC patients

Multivariate Cox’s proportional hazards regression analysis showed that CDC42 quartile 3 (vs. quartile 1) (HR = 7.383, p = 0.013), CDC42 quartile 4 (vs. quartile 1) (HR = 7.363, p = 0.011), ECOG PS score of 1 (vs. 0) (HR = 2.270, p = 0.032), T4 (vs. T1 or T2) stage (HR = 53.084, p = 0.018), and N2 (vs. N0) stage (HR = 7.927, p < 0.001) were independently correlated with declined OS (Table 5).

In addition, higher ECOG PS score (P = 0.018) (Supplementary Figure S1A), higher T stage (P < 0.001) (Supplementary Figure S1B), elevated N stage (p < 0.001) (Supplementary Figure S1C), and poor tumor differentiation (p = 0.003) (Supplementary Figure S1D) were correlated with declined DFS; meanwhile, higher ECOG PS score (p = 0.034) (Supplementary Figure S1E), higher T stage (p < 0.001) (Supplementary Figure S1F), and elevated N stage (p < 0.001) (Supplementary Figure S1G) were associated with decreased OS.

4 | DISCUSSION

It has been reported that CDC42 is highly expressed in CRC tissues. While the blood CDC42 in CRC patients is unclear. In the present study, we discovered that blood CDC42 was upregulated in CRC patients compared to HCs, which also had a good ability to distinguish CRC patients from HCs. The possible explanations might be that: (1) CDC42 might suppress the CD8+ T cells activation and promote the immune escape of CRC cells, which could accelerate the tumorigenesis of CRC; (2) CDC42 could elevate macrophage recruitment, consequently promoting the pathogenesis of CRC.

Thereby, blood CDC42 was increased in CRC patients. The correlation of CDC42 with clinical features among cancer patients has been paid a lot of attention. For instance, an interesting study has presented that blood CDC42 is not linked to patients’ demographic information and comorbidities (such as hypertension, hyperlipidemia, and diabetes), while it is related to elevated lymph node metastasis, higher TNM stage, and rising ECOG PS score among lung cancer patients. However, the data about the relation of blood CDC42 with clinical characteristics among CRC patients are scarce. The present study discovered that blood CDC42 was linked to higher T stage, N stage, TNM stage, abnormal CEA, and adjuvant therapy administration among CRC patients. The potential explanation might be that: (1) CDC42 could suppress CD8+ T cells activation and promote the immune escape, consequently inducing the tumor growth and invasion, which resulted in higher T, N, and TNM stages; (2) CDC42 might be able to directly accelerate tumor growth and invasion through several pathways, such as vascular endothelial growth factor and membrane-anchored neuropilin-1 signalings, which could lead to elevated T, N, and TNM stages; (3) CDC42 could accelerate tumor growth and invasion, as well as correlate with higher T, N, and TNM stage (above-mentioned), which led to the increment of tumor marker (CEA); (4) CDC42 was related to higher TNM stage (above-mentioned); meanwhile, TNM stage could critically affect whether patients would receive adjuvant therapy.

TABLE 2 Correlation of CDC42 expression with demographics and comorbidities in CRC patients

| Items               | CDC42 expression | Statistics (χ²) | p Value |
|---------------------|------------------|-----------------|---------|
| Age, n (%)          |                  |                 |         |
| ≤60 years           | 30 (48.4)        | 1.751           | 0.186   |
| >60 years           | 32 (51.6)        |                 |         |
|                     |                  |                 |         |
| Gender, n (%)       |                  |                 |         |
| Female              | 22 (35.5)        | 0.591           | 0.442   |
| Male                | 40 (64.5)        |                 |         |
|                     |                  |                 |         |
| Smoker, n (%)       |                  |                 |         |
| No                  | 41 (66.1)        | 0.956           | 0.328   |
| Yes                 | 21 (33.9)        |                 |         |
|                     |                  |                 |         |
| Hypertension, n (%) |                  |                 |         |
| No                  | 43 (69.4)        | 0.835           | 0.361   |
| Yes                 | 19 (30.6)        |                 |         |
|                     |                  |                 |         |
| Hyperlipidemia, n (%) |                |                 |         |
| No                  | 51 (82.3)        | 0.298           | 0.585   |
| Yes                 | 11 (17.7)        |                 |         |
|                     |                  |                 |         |
| Diabetes, n (%)     |                  |                 |         |
| No                  | 54 (87.1)        | 3.087           | 0.079   |
| Yes                 | 8 (12.9)         |                 |         |

Abbreviations: CDC42, cell division cycle 42; CRC, colorectal cancer.
chemotherapy, thus, CDC42 was correlated with adjuvant chemotherapy administration.

The relation of CDC42 with survival profile among cancer patients has been investigated. For instance, blood CDC42 is negatively associated with unsatisfactory DFS and OS among lung cancer patients; moreover, it also has been proposed that the increment of CDC42 in tumor tissue leads to an unfavorable prognosis among ovarian cancer and CRC patients. While the correlation of blood CDC42 with survival among CRC patients is unclear. In the present study, we first discovered that higher CDC42 quartiles were correlated with declined DFS and OS; then, CDC42 was also divided into low expression and high expression for analysis, which illustrated that CDC42 high (vs. low) was also linked to decreased DFS and OS; subsequently, multivariate Cox's proportional hazards regression analysis presented that higher CDC42 quartile was independently related to declined DFS and OS.

### Table 3

Correlation of CDC42 expression with tumor features, tumor marker and adjuvant treatment information in CRC patients

| Items                        | CDC42 expression | Statistics ($\chi^2$) | p Value |
|------------------------------|------------------|-----------------------|---------|
|                              | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |                      |
| Diagnosis, n (%)             |            |            |            |            | 0.443                | 0.506                |
| Colon                        | 42 (67.7) | 42 (66.7) | 38 (60.3) | 47 (75.8) |
| Rectum                       | 20 (32.3) | 21 (33.3) | 25 (39.7) | 15 (24.2) |
| ECOG PS, n (%)               |            |            |            |            | 1.287                | 0.257                |
| 0                            | 35 (56.5) | 36 (57.1) | 31 (49.2) | 30 (48.4) |
| 1                            | 27 (43.5) | 27 (42.9) | 32 (50.8) | 32 (51.6) |
| Tumor differentiation, n (%) |            |            |            |            | 2.669                | 0.102                |
| Well                         | 15 (24.2) | 12 (19.0) | 12 (19.0) | 7 (11.3) |
| Moderate                     | 28 (45.2) | 29 (46.1) | 30 (47.6) | 30 (48.4) |
| Poor                         | 19 (30.6) | 22 (34.9) | 21 (33.4) | 25 (40.3) |
| Tumor size, n (%)            |            |            |            |            | 2.605                | 0.107                |
| <5 cm                        | 45 (72.6) | 43 (68.3) | 40 (63.5) | 37 (59.7) |
| ≥5 cm                        | 17 (27.4) | 20 (31.7) | 23 (36.5) | 25 (40.3) |
| T stage, n (%)               |            |            |            |            | 15.787               | <0.001               |
| T1                           | 3 (4.8)    | 2 (3.2)    | 1 (1.6)    | 0 (0.0)   |
| T2                           | 11 (17.7)  | 10 (15.8)  | 5 (7.9)    | 1 (1.6)   |
| T3                           | 48 (77.5)  | 51 (81.0)  | 56 (88.9)  | 59 (95.2) |
| T4                           | 0 (0.0)    | 0 (0.0)    | 1 (1.6)    | 2 (3.2)   |
| N stage, n (%)               |            |            |            |            | 6.906                | 0.009                |
| N0                           | 47 (75.8)  | 38 (60.3)  | 37 (58.7)  | 32 (51.6) |
| N1                           | 11 (17.7)  | 17 (27.0)  | 16 (25.4)  | 20 (32.3) |
| N2                           | 4 (6.5)    | 8 (12.7)   | 10 (15.9)  | 10 (16.1) |
| TNM stage, n (%)             |            |            |            |            | 14.676               | <0.001               |
| Stage I                      | 14 (22.6)  | 12 (19.0)  | 6 (9.5)    | 1 (1.6)   |
| Stage II                     | 33 (53.2)  | 26 (41.3)  | 31 (49.2)  | 31 (50.0) |
| Stage III                    | 15 (24.2)  | 25 (39.7)  | 26 (41.3)  | 30 (48.4) |
| CEA, n (%)                   |            |            |            |            | 4.080                | 0.043                |
| Normal                       | 43 (69.4)  | 38 (60.3)  | 36 (57.1)  | 32 (51.6) |
| Abnormal                     | 19 (30.6)  | 25 (39.7)  | 27 (42.9)  | 30 (48.4) |
| Adjuvant chemotherapy, n (%) |            |            |            |            | 9.168                | 0.002                |
| No                           | 19 (30.6)  | 18 (28.6)  | 10 (15.9)  | 7 (11.3)  |
| Yes                          | 43 (69.4)  | 45 (71.4)  | 53 (84.1)  | 55 (88.7) |
| Adjuvant regimen, n (%)      |            |            |            |            | 1.561                | 0.212                |
| Capecitabine                 | 13 (30.2)  | 10 (22.2)  | 16 (30.2)  | 9 (16.4)  |
| CapeOx                       | 30 (69.8)  | 35 (77.8)  | 37 (69.8)  | 46 (83.6) |

Abbreviations: CapeOX, capecitabine plus oxaliplatin; CDC42, cell division cycle 42; CEA, carcinoembryonic antigen; CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status.
The above data indicated that blood CDC42 might have the potential to serve as the prognosis biomarker in CRC. The potential explanations might be that (1) blood CDC42 was directly correlated with poor tumor features among CRC patients (above-mentioned); thus, CDC42 was indirectly associated with declined DFS and OS. (2) CDC42 could promote the immune escape of tumor cells, which might elevate the risk of tumor recurrence, consequently resulting in unfavorable DFS and OS\(^{10,13}\); (3) CDC42 could induce drug resistance through promoting transcription factor SRY-box transcription factor 2, consequently attenuate the efficacy of adjuvant chemotherapy and resulting in poor prognosis among CRC patients.\(^{25}\) Thereby, blood CDC42 was related to declined DFS and OS among CRC patients. Apart from that, we also discovered that higher ECOG PS score, poor differentiation, and higher T and N stage were also independently predicted poor prognosis among CRC patients, indicating patients with these clinical features should be more attention by clinicians.

The reasons for detecting blood CDC42 among CRC patients were as follows: (1) it was convenient to acquire blood samples with less harm among patients and (2) blood samples could be obtained before surgical resection, which could facilitate the early classification and management of patients. However, the present study exited some limitations: (1) as a single-center study, the generalization of research might be affected by selection bias; (2) CRC patients with distant metastases were excluded in the present study; hence, the clinical role of blood CDC42 in these patients could be explored; (3) the underlying mechanism of CDC42 in the progression of CRC could be discovered in the future; (4) because CDC42 could regulate CD8\(^+\) T cells and immune escape, the association of CDC42 with immunotherapy could be investigated among CRC patients later; (5) the modulation of CDC42 in CD8\(^+\) T cell activation and immune escape among CRC patients could be investigated in the future; and (6) we only detected the mRNA expression of CDC42 in the current study, the protein expression of CDC42 could be explored in the forthcoming research.
### TABLE 4
Independent factors related to DFS by multivariate Cox's proportional hazards regression analysis with forward-stepwise mode

| Items                  | p value | HR    | 95% CI          |
|------------------------|---------|-------|-----------------|
|                        |         |       |                 |
| CDC42 expression       |         |       |                 |
| Quartile 1 Ref.        |         |       |                 |
| Quartile 2             | 0.304   | 1.667 | 0.629 4.413     |
| Quartile 3             | 0.024   | 2.872 | 1.148 7.185     |
| Quartile 4             | 0.007   | 3.398 | 1.394 8.283     |
| ECOG PS                |         |       |                 |
| 0 Ref.                 |         |       |                 |
| 1                      | 0.017   | 1.976 | 1.132 3.451     |
| Tumor differentiation  |         |       |                 |
| Well                   |         |       |                 |
| Moderate               | 0.431   | 1.638 | 0.479 5.594     |
| Poor                   | 0.042   | 3.513 | 1.046 11.799    |
| T stage                |         |       |                 |
| T1 or T2 Ref.          |         |       |                 |
| T3                     | 0.519   | 1.498 | 0.439 5.108     |
| T4                     | <0.001  | 60.463| 6.971 524.414   |
| N stage                |         |       |                 |
| N0 Ref.                |         |       |                 |
| N1                     | 0.352   | 0.690 | 0.315 1.509     |
| N2                     | <0.001  | 3.221 | 1.706 6.080     |

Abbreviations: CDC42, cell division cycle 42; CI, confidence interval; DFS, disease-free survival; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio.

### TABLE 5
Independent factors related to OS by multivariate Cox's proportional hazards regression analysis with forward-stepwise mode

| Items                  | p value | HR    | 95% CI          |
|------------------------|---------|-------|-----------------|
|                        |         |       |                 |
| CDC42 expression       |         |       |                 |
| Quartile 1 Ref.        |         |       |                 |
| Quartile 2             | 0.118   | 3.624 | 0.720 18.239    |
| Quartile 3             | 0.013   | 7.383 | 1.530 35.638    |
| Quartile 4             | 0.011   | 7.363 | 1.587 34.163    |
| ECOG PS                |         |       |                 |
| 0 Ref.                 |         |       |                 |
| 1                      | 0.032   | 2.270 | 1.071 4.810     |
| T stage                |         |       |                 |
| T1 or T2 Ref.          |         |       |                 |
| T3                     | 0.836   | 1.248 | 0.152 10.228    |
| T4                     | 0.018   | 53.084| 1.982 1421.918  |
| N stage                |         |       |                 |
| N0 Ref.                |         |       |                 |
| N1                     | 0.422   | 1.528 | 0.543 4.294     |
| N2                     | <0.001  | 7.927 | 3.283 19.143    |

Abbreviations: CDC42, cell division cycle 42; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; OS, overall survival.
To be conclusive, circulating CDC42 relates to higher disease risk, T, N, and TNM stage, abnormal tumor marker, and poor prognosis among CRC patients, suggesting that circulating CDC42 may be served as a biomarker to help the early stratification of CRC patients, thus improving their management.

ACKNOWLEDGMENTS
This study was supported by Scientific Research fund of Hebei Health Commission (No. 20180813).

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

DATA AVAILABILITY STATEMENT
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

ORCID
Shuquan Gao (https://orcid.org/0000-0001-5231-3875)

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
3. O’Sullivan DE, Sutherland RL, Town S, et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(6):1229-1240. e1225.
4. Kanth P, Inadomi JM. Screening and prevention of colorectal cancer. BMJ. 2021;374:n1855.
5. Longstreth GF, Anderson DS, Zisook DS, Shi JM, Lin JC. Low rate of cancer detection by colonoscopy in asymptomatic, average-risk subjects with negative Results from fecal immunochemical tests. Clin Gastroenterol Hepatol. 2020;18(13):2929-2936. e2921.
6. Sincrope FA, Chakrabarti S, Laurent-Puig P, et al. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Eur J Cancer. 2021;144:101-112.
7. Edwards GC, Gamboa AC. Feng MP, et al. What’s the magic number? Impact of time to initiation of treatment for rectal cancer. Surgery. 2022;171(5):1185-1192.
8. Guo F. RhoA and Cdc42 in T cells: are they targetable for T cell-mediated inflammatory diseases? Precis Clin Med. 2021;4(1):56-61.
9. Crosas-Molist E, Samain R, Kohlihammer L, et al. Rho GTPase signaling in cancer progression and dissemination. Physiol Rev. 2022;102(1):455-510.
10. Jaksits S, Bauer W, Kriehuber E, et al. Lipid raft-associated GTPase signaling controls morphology and CD8+ T cell stimulatory capacity of human dendritic cells. J Immunol. 2004;173(3):1628-1639.
11. Guo F, Zhang S, Tripathi P, et al. Distinct roles of Cdc42 in thymopoiesis and effector and memory T cell differentiation. PLoS ONE. 2011;6(3):e18002.
12. Wurzer H, Filali L, Hoffmann C, et al. Intrinsic resistance of chronic lymphocytic leukemia cells to NK cell-mediated lysis can be overcome in vitro by pharmacological inhibition of Cdc42-induced Actin cytoskeleton remodeling. Front Immunol. 2021;12:619069.
13. Marques CA, Hahnel PS, Wolff C, et al. An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression. Blood. 2008;111(3):1413-1419.
14. Ke TW, Hsu HL, Wu YH, Chen WT, Cheng YW, Cheng CW. MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42. Dis Markers. 2014;2014:617150.
15. Gao L, Bai L, Nan Q. Activation of rho GTPase Cdc42 promotes adhesion and invasion in colorectal cancer cells. Med Sci Monit Basic Res. 2013;19:201-207.
16. Ma LL, Guo LL, Luo Y, et al. Cdc42 subcellular relocation in response to VEGF/NRP1 engagement is associated with the poor prognosis of colorectal cancer. Cell Death Dis. 2020;11(3):171.
17. Kazmi N, Robinson T, Zheng J, Kar S, Martin RM, Ridley AJ. Rho GTPase gene expression and breast cancer risk: a mendelian randomization analysis. Sci Rep. 2022;12(1):1463.
18. Yan J, Wan D. Dysregulation of circulating CDC42 and its correlation with demographic characteristics, comorbidities, tumor features, chemotherapeutic regimen and survival profile in non-small-cell lung cancer patients. J Clin Lab Anal. 2022;36(2):e24140.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C[T]) method. Methods. 2001;25(4):402-408.
20. Gomez Del Pulgar T, Valdes-Mora F, Bandres E, et al. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol. 2008;33(1):185-193.
21. Zhang B, Zhang J, Xia L, et al. Inhibition of CDC42 reduces macrophage recruitment and suppresses lung tumorigenesis in vivo. J Recept Signal Transduct Res. 2021;41(5):504-510.
22. Yang QJ, Kalim KW, Li Y, et al. Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation. Clin Exp Allergy. 2019;49(1):92-107.
23. Zhang H, Liu Y, Wang C, et al. A modified tumor-node-metastasis staging system for colon cancer patients with fewer than twelve lymph nodes examined. World J Surg. 2021;45(8):2601-2609.
24. Guo Y, Kenney SR, Cook L, et al. A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients. Clin Cancer Res. 2015;21(22):5064-5072.
25. Ye Y, Zhang R, Feng H. Fibronectin promotes tumor cells growth and drugs resistance through a CDC42-YAP-dependent signaling pathway in colorectal cancer. Cell Biol Int. 2020;44(9):1840-1849.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Gao S, Xue J, Wu X, Zhong T, Zhang Y, Li S. The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients. J Clin Lab Anal. 2022;36:e24572. doi: 10.1002/jcla.24572